Gilead Sciences has entered into a definitive merger agreement to acquire Arcellx, Inc. through a tender offer priced at $115.00 per share in cash. Additionally, shareholders will receive one contingent value right (CVR) per share, which offers a potential $5.00 cash payment upon the achievement of specific sales milestones for the product anito-cel by December 31, 2029.
